top of page

News

Princeton, NJ, August 21, 2023 iQure Pharma Inc. (iQure), a US-based biotech company, has completed its key go/no go criteria enabling the start of the GLP Tox package with iQ-007, a novel anticonvulsant compound.


iQure is pleased to announce that it has completed two additional iQ-007 studies. First, a CaCo-2 test was performed demonstrating the high permeability of the compound and the lack of interaction with transporters, thereby increasing the drug ability of the compound. Second, a Cytotoxicity test was performed to confirm the initial results of lack of cytotoxic behavior of the compound. “With these positive results, the final go/no-go criteria has been achieved and we will now move full speed ahead with our main toxicology studies, beginning next month with the first Maximum Tolerated Dose (MTD) and two-week toxicology study in rats, which is an important step towards IND, scheduled for Q3 2024,” said Henk de Wilde, iQure Pharma’s Chief Operating Officer.


About iQure Pharma

iQure Pharma, a global biotech firm headquartered in the US, is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies. For more information about supporting iQure’s initiatives, contact iQure CFO Dr. Anna Rzewuska at anna.rzewuska@iqurepharma.com.

Princeton, NJ, July 6, 2023 ─ iQure Pharma Inc. (iQure), a US-based global biotech company, has been awarded a second patent for iQure-007, its novel therapeutic currently in development for the treatment of epilepsy.


“We are delighted with this second patent being granted for iQ-007,” said iQure Chief Executive Officer Pawel Zolnierczyk. “This is an important step in the process of commercializing this promising asset for the treatment of Drug Resistant Epilepsy. Patent protections are pivotal to maintaining the value of our assets. With the award of this second patent, we now have expanded protection and even better potential for securing market position.”


Recent experiments confirmed that iQ-007 acts as a positive allosteric modulator of naturally occurring neuromodulator EAAT2. Through this unique mechanism, it enhances the natural glutamate uptake preventing neurotoxicity, associated with epilepsy and neuropathic pain.



About iQure Pharma

iQure Pharma, a global biotech firm headquartered in the US, is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies. For more information about supporting iQure’s initiatives, contact iQure CFO, Dr. Anna Rzewuska at anna.rzewuska@iqurepharma.com.

Princeton, NJ, June 27, 2023 ─ iQure Pharma Inc. (iQure), a US-based global biotech company, has achieved another milestone towards IND by passing a significant cardiac safety test with iQ-007, their signature novel anti-convulsant compound.


iQure is pleased to announce that the specific affinity of iQ-007 towards the cardiac-selective binding channels, Nav1.5, Cav1.2 and hERG, were tested, and no binding was detected compared to the active reference compounds. Many anti-epileptic drugs have the potential for cardiac side effects, so it is crucial to eliminate this risk in the early stages of development. The latest results are in line with previous tests on non-selective sodium and calcium channels, which already proved negative. This shows once again the highly selective mechanism of iQ-007 as a positive allosteric modulator of the EAAT2 transporter.


"Cardiac safety is very important for a prospective medication like iQ-007, which is intended for mid- and long-term use. Here at iQure, we are mindful of how important quality of life is for patients and their families,” said iQure Chief Executive Officer, Pawel Zolnierczyk. “With these results, we can continue our efforts to advance iQ-007 to clinical trials, and ultimately offer patients an effective and safe therapy.”


About iQure Pharma

iQure Pharma, a global biotech firm headquartered in the US, is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies. For more information about supporting iQure’s initiatives, contact iQure CFO, Dr. Anna Rzewuska at anna.rzewuska@iqurepharma.com.


JPM Week
No Abuse
bottom of page